17:17 , May 11, 2018 |  BC Week In Review  |  Financial News

Neurana closes $60M series A

Neurana Pharmaceuticals Inc. (San Diego, Calif.) closed a $60 million series A round led by Sofinnova Ventures. Also participating were New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital Management and MagnaSci Ventures. Neurana has...
21:46 , May 7, 2018 |  BC Extra  |  Financial News

Neurana closes $60M series A

Neurana Pharmaceuticals Inc. (San Diego, Calif.) closed a $60 million series A round led by Sofinnova Ventures. Also participating were New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital Management and MagnaSci Ventures. Neurana has...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Katama Pharmaceuticals, Sanochemia deal

Sanochemia granted newco Katama exclusive rights in North America to develop and commercialize spasticity product tolperisone. Katama will initially develop the small molecule muscle relaxant for acute, painful muscle spasms. The company plans to start...
00:38 , Oct 6, 2012 |  BC Extra  |  Company News

Newco Katama in deal for Sanochemia's tolperisone

Sanochemia Pharmazeutika AG (Xetra:SAC) granted newco Katama Pharmaceuticals Inc. (San Diego, Calif.) exclusive rights in North America to develop and commercialize spasticity product tolperisone. Katama will initially develop the small molecule muscle relaxant for acute,...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Myderison tolperisone regulatory update

EMEA's CHMP said that after an arbitration procedure following a disagreement among EU member states the agency concluded that the benefits did not outweigh the risks for Meditop's Myderison tolperisone to treat skeletal muscle spasticity....
08:00 , Jan 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Although biotech banking hasn't looked like a growth opportunity, the combination of...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Avigen, Baxter, MediciNova deal

MediciNova disclosed that it made an unsolicited offer to acquire Avigen for 1.8 million shares and a convertible security equal to Avigen's net cash, less $7 million that would go to MediciNova. The shares are...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

4Q approvals

4Q approvals...
02:04 , Dec 24, 2008 |  BC Extra  |  Company News

MediciNova bids for Avigen

On Tuesday, MediciNova (NASDAQ:MNOV; Osaka:4875) disclosed that it made an unsolicited offer on Monday to acquire Avigen (NASDAQ:AVGN) for 1.8 million shares and a convertible security equal to Avigen's net cash, less $7 million. The...
08:00 , Dec 15, 2008 |  BioCentury  |  Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled...